BusinessAGI reports $45 million Q3 revenue, secures FDA acceptance for AG-101AGI (AGBK) reported $45 million in Q3 2026 revenue but incurred a net loss of $119 million, while securing FDA acceptance for its lead gene therapy candidate AG-101 and forming a partnership for a new...Nasdaq News · 2 days ago · 2 min read